Minerva Neurosciences (NERV) Intangibles (2013 - 2024)
Minerva Neurosciences' (NERV) quarterly Intangibles came in at $4257.0 in Q2 2024, down 85.71% YoY from $29797.0 in Q3 2023, and down 60.0% on a QoQ basis from $10642.0 in Q1 2024.
Analysis
Minerva Neurosciences (NERV) Intangibles (2013 - 2024) Analysis & Trends
Minerva Neurosciences (NERV) has 12 years of Intangibles data on file, last reported at $4257.0 in Q2 2024.
- Quarterly Intangibles fell 85.71% year-over-year to $4257.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $4257.0 (down 85.71% YoY) and the FY2023 annual result came in at $17027.0, down 60.0% from the prior year.
- Intangibles eased to $4257.0 in Q2 2024, from $10642.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $15.2 million in Q1 2020 to a low of $4257.0 in Q2 2024.
- A 5-year average of $5.1 million and a median of $51080.0 in 2021 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2020 — Intangibles changed 0.0% — and 2021, when it sank 99.66%.
- Tracing NERV's Intangibles over 5 years: stood at $15.2 million in 2020, then slumped by 99.66% to $51080.0 in 2021, then decreased by 16.67% to $42567.0 in 2022, then slumped by 60.0% to $17027.0 in 2023, then sank by 75.0% to $4257.0 in 2024.
- The last three Intangibles figures came in at $4257.0 (Q2 2024), $10642.0 (Q1 2024), and $17027.0 (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 63.28 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 60.96 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 4,257.00 |
| Mar 31, 2024 | 10,642.00 |
| Dec 31, 2023 | 17,027.00 |
| Sep 30, 2023 | 23,412.00 |
| Jun 30, 2023 | 29,797.00 |
| Mar 31, 2023 | 36,182.00 |
| Dec 31, 2022 | 42,567.00 |
| Sep 30, 2022 | 48,952.00 |
| Jun 30, 2022 | 51,080.00 |
| Mar 31, 2022 | 51,080.00 |
| Dec 31, 2021 | 51,080.00 |
| Sep 30, 2021 | 15.20 Mn |
| Jun 30, 2021 | 15.20 Mn |
| Mar 31, 2021 | 15.20 Mn |
| Dec 31, 2020 | 15.20 Mn |
| Sep 30, 2020 | 15.20 Mn |
| Jun 30, 2020 | 15.20 Mn |
| Mar 31, 2020 | 15.20 Mn |
| Dec 31, 2019 | 15.20 Mn |
| Sep 30, 2019 | 34.20 Mn |